SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-24-068054
Filing Date
2024-03-14
Accepted
2024-03-14 17:28:12
Documents
5
Effectiveness Date
2024-03-14

Document Format Files

Seq Description Document Type Size
1 S-8 d794229ds8.htm S-8 46661
2 EX-5.1 d794229dex51.htm EX-5.1 9909
3 EX-23.1 d794229dex231.htm EX-23.1 1647
4 EX-FILING FEES d794229dexfilingfees.htm EX-FILING FEES 21752
5 GRAPHIC g794229g0313023634927.jpg GRAPHIC 2233
  Complete submission text file 0001193125-24-068054.txt   84242
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-277954 | Film No.: 24751380
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)